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Abstract 
Objectives: Systemic lupus erythematosus (SLE) is an autoimmune disease that can lead to unfavorable pregnancy 
complications in women. This study aimed to evaluate the factors associated with pregnancy outcomes in patients 
with SLE.
Results: Fifty-nine pregnant women with SLE (121 pregnancies) participated in this retrospective cohort study. The 
mean age of the patients was 33.74 ± 3.80 years (range 21 to 48 years). Fetal loss occurred in 43.8% of pregnancies. 
The most common laboratory findings in SLE patients were antinuclear antibody (81.4%) and anti-ds DNA positiv-
ity (54.2%). High levels of C-reactive protein (CRP) during pregnancy, renal involvement, anti-double-stranded DNA 
positivity, anti-phospholipid antibody (APA) positivity and younger age at disease onset were significantly correlated 
with unfavourable pregnancy outcomes. A significant difference was observed between duration of SLE and low 
birth weight (P = 0.003), pre-eclampsia (P = 0.012) and still birth (P = 0.036). High CRP, APA positivity, anti-dsDNA 
positivity and kidney involvement were predictors of adverse pregnancy outcomes in SLE patients. Renal involvement 
increased risk of pregnancy with complication 8.5 times (OR = 8.5, 95% CI 1.396–63.373, P = 0.017). Antiphospholipid 
syndrome (APS) also was associated with an odds ratio of 5.18 (95% CI 1.681–13.647, P = 0.001).
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Introduction
Systemic lupus erythematosus (SLE) is an autoimmune 
disease with an annual incidence of 4–35 cases per 
100,000 people, which predominantly find in females 
of child-bearing age [1]. Disease relapse can occur in 
throughout the entire pregnancy and often immedi-
ately after termination of pregnancy. Several studies 
reported the SLE relapse during pregnancy and consid-
ered an important role for estrogen in causing disease [2]. 
Although the majority of studies showed an increased 
SLE relapse during pregnancy, but some believe that the 
frequency of flares during pregnancy is similar to non-
pregnancy [2–4]. In a study conducted by Urowits et al., 
disease activity at the onset of pregnancy did not predict 
the risk of exacerbation during pregnancy. They reported 
that patients with inactive SLE less likely to experience 
a flare of disease [5]. However, methodological differ-
ences and the use of different sample sizes may be the 
cause of discrepancies in the obtained results. A lupus 
flare during pregnancy is dependent on disease’s activ-
ity at the time of fertilization. The frequency of flare has 
been reported 7–33% in women who were in remission 
for at least 6 months before conception, while 61–67% of 
patients with active SLE at the onset of pregnancy have 
been a disease flare. However, there is no consensus 
among researchers that increased lupus activity is due to 
pregnancy or spontaneous fluctuation of disease [6–8].
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Some pregnancy adverse outcomes can be related to 
SLE, including pre-eclampsia, abortion, preterm birth, 
stillbirth, and fetal growth restriction. A recent meta-
analysis study showed that the SLE had a high impact on 
maternal and fetal outcomes following pregnancy. Pre-
eclampsia and hypertension had significantly higher rates 
among women with SLE (relative risk (RR): 1.85 1.91, 
95% confidence interval (CI) 1.44–2.53; P = 0.00001) and 
(RR: 1.99, 95% CI 1.54–2.56; P = 0.00001) respectively. In 
addition, thromboembolic disease and abortion were also 
significantly higher in the SLE patients [9]. Nevertheless, 
several studies have shown SLE to have unfavorable preg-
nancy outcomes, the factors associated with such com-
plications seem to be varied from region to region. There 
are limited studies conducted on pregnancy outcomes 
among Iranian women with SLE. Considering the high 
prevalence of SLE in women and importance of mater-
nal–fetal health, this study aimed to evaluate factors 
associated with pregnancy outcome in patients with sys-
temic lupus erythematosus.
Main text
Methods and materials
Total pregnant women with SLE (59 patients, 121 preg-
nancies) referred to the rheumatology clinic at the Sha-
hid Beheshti Hospital of Kashan University of Medical 
Sciences in Kashan City between 2003 and 2017 were 
participated in this retrospective cohort study. Study 
population included pregnant women with pre-existing 
SLE and new onset SLE. All SLE patients had the Ameri-
can college of rheumatology diagnostic criteria. Disease 
activity was estimated based on the systemic lupus ery-
thematosus disease activity index (SLEDAI). Patients 
were categorized into three groups, according to SLEDAI 
score: remission (6>), mild to moderate activity [6–12] 
and high activity (>12). The medical records of patients 
were comprehensively reviewed to collect demographic, 
clinical and laboratory data. Recorded findings included 
age, duration of illness, disease activity, blood pressure, 
drugs, number of pregnancies, abortion and intrauter-
ine fetal death. Patients with incomplete medical records 
were excluded from the study. Laboratory parameters 
included complete blood cell (CBC), erythrocyte sedi-
mentation rate (ESR), C-reactive protein (CRP), and 
venereal disease research laboratory (VDRL). Immuno-
logic parameters, including total complement activity 
(CH50: 101–300) anti-double-stranded DNA antibod-
ies (anti-dsDNA: < 70  IU/mL), antiphospholipid anti-
bodies (APA: < 10  IU/mL), complement 3 (90–180  mg/
dL), and complement 4 (13–75  mg/dL) were evaluated 
by enzyme-linked immunosorbent assay (ELISA). Anti-
nuclear antibodies (ANA: < 1:80) were measured by 
indirect immunofluorescence assay (IFA). All patients 
were followed up during pregnancy by a gynecologist, 
nephrologist and rheumatologist. Maternal complica-
tions, including PROM (rupture of membranes prior 
to the onset of labor at or beyond 37  weeks’ gestation), 
Pre-eclampsia (systolic blood pressure ≥ 140  mmHg 
and/or diastolic blood pressure (DBP) ≥ 90  mmHg after 
20  weeks of gestation in a previously normotensive 
woman). In addition, outcomes related to fetal, includ-
ing LBW (a birth weight of less than 2500  g), stillbirth 
(fetal death ≥ 20 weeks of gestation), abortion (pregnancy 
termination before 20  weeks’ gestation or with a fetus 
born weighing < 500  g, and Preterm labor (birth before 
37 weeks of pregnancy) were checked by a pediatrician.
Statistical analysis
The statistical analysis was conducted using the Statisti-
cal Package for Social Sciences (SPSS) version 21.0 (SPSS 
Inc, Chicago, IL, USA). Qualitative data were analyzed 
by Chi-square test and Fisher’s exact test. The continu-
ous variables were analyzed by using Student’s t test. 
Variables with a P ≤ 0.10 in these analyses were entered 
into a multiple logistic regression model to determine the 
predictive factors for adverse pregnancy outcomes with 
adjustment of confounding factors. Adjusted odds ratios 
(OR) are presented at 95% confidence intervals (CI). In all 
tests, P values less than 0.05 were considered to be statis-
tically significant.
Results
In this study, 121 pregnancies in 59 SLE patients were 
evaluated between 2003 and 2017. The mean age of 
the patients was 33.74 ± 3.80  years ranging from 21 to 
48  years old. A total of 96 pregnancies (79.3%) were 
linked to adverse outcomes. Abortion and stillbirth 
occurred in 47 (38.8%) and 6 (5%) pregnancies, respec-
tively. Thirty-eight of pregnancies (56.2%) led to a live 
birth. The most abundant laboratory findings in SLE 
patients were antinuclear antibody (81.4%) and Anti-
ds DNA positivity (54.2%). Six patients had a history of 
lupus nephritis (three cases with class IV nephritis, two 
cases with class II, and one case with class III) Renal 
involvement (10.2%) and CRP test before pregnancy 
(11.9%) was less common. Pregnancy occurred in 117 
cases (97%) in the quiescent phase of SLE, and in cases 
with active diseases (3%). Twenty-three women had a 
relapse of SLE (19%). Fifty-seven pregnant women (97%) 
had pre-existing lupus, while two women (3%) referred 
with SLE onset in pregnancy. Patients during pregnancy 
received 5–10  mg Prednisolone and 200  mg Hydroxy-
chloroquine daily. Frequency of pregnancy complications 
according to laboratory findings in pregnant women 
with SLE is summarized in Table 1. There was a signifi-
cant correlation between ANA positivity and abortion 
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(P = 0.016) or preterm birth (P = 0.002). Increasing ESR, 
high CRP during pregnancy and renal involvement was 
significantly associated with stillbirth. Occurrence of 
poor outcomes, including PROM, LBW, pre-eclampsia, 
preterm labor and stillbirth was correlated with mater-
nal anti-dsDNA positivity. Antiphospholipid antibod-
ies (APA) were detected in 46 patients (38%). Presence 
of APA antibody in pregnant women was significantly 
linked with abortion (P = 0.017).
Pregnancy in 4.3% of women who had a duration of 
SLE less than 5  years led to LBW. This complication in 
patients with a duration ≥ 6  years was 21.6%. A signifi-
cant difference was observed between SLE duration and 
LBW (P = 0.003), pre-eclampsia (P = 0.012), stillbirth 
(P = 0.036) (Table 2).
Logistic regression analysis was performed to assess the 
association of laboratory findings and adverse pregnancy 
outcomes (Table 3). High CRP during pregnancy, kidney 
involvement, anti ds-DNA positivity, APA positivity and 
younger ages at disease onset was significantly correlated 
with severe pregnancy complications. Renal involvement 
was the most important factor associated with pregnancy 
outcomes and increased the risk of complicated preg-
nancy 8.5 times (OR = 8.545, CI 1.396–63.373, P = 0.017). 
Antiphospholipid syndrome (APS) also was associ-
ated with an odds ratio of 5.18 (95% CI 1.681–13.647, 
P = 0.001). Pregnancy complications were higher in 
younger SLE patients. Increasing every 1  year in age of 
disease onset decreased 93% of risk of a pregnancy with 
complication (OR: 0.932, 95% CI 0.865–1.009).
Discussion
Despite the recent progress in management of pregnant 
women with SLE, results of the present study show that 
SLE during pregnancy is still associated with the inci-
dence of adverse pregnancy outcomes. One hundred 
twenty-one pregnancies were occurred in 59 women with 
SLE. Spontaneous abortion, preterm labor, SLE relapse 
and stillbirth were observed in 38.8%, 25.6%, 19% and 5% 
of pregnancies, respectively.
In this study, fetal loss of 43.8% was observed, which is 
high compared to other reports. In the previous studies, 
abortion has been one of the most common pregnancy 
outcomes in women with SLE. This complication in 
study of Yuen et al. [10] and Parastandechehr et al. [11] 
were reported 19.5% and 19%, respectively. Clowse and 
colleagues were founded that the activity of SLE during 
pregnancy led to a threefold increase in spontaneous 
abortion [12]. Fetal loss, including abortion and stillbirth 
in the study of Park et al. was 17.7% [13]. In the present 
study, abortion incidence is higher than the above-men-
tioned researches) 38.8%), because many women with 
frequent abortion were referred to Kashan’s rheumatol-
ogy clinic to find the cause of their fetal loss. Diagnosis of 
lupus in these women is a possible reason for increasing 
the incidence of abortion in our study.
In the current study, live-birth rate in SLE patients 
was 56.2%, which is less than the 80.5–91.9% reported 
in other studies. Preterm birth was occurred in 25.8% of 
pregnancies. Many studies have reported a high rate of 
preterm birth as an adverse pregnancy outcome in SLE 
patients. The frequency of this complication in stud-
ies conducted by Limba et al. [14], Smyth et al. [4], Park 
et  al. [13] and Megan et  al. [12] were 43%, 39%, 25.5% 
and 23.7%, respectively. In this study, pre-eclampsia 
observed in 15.7% of patients. Previous similar studies 
have reported a wide range of pre-eclampsia in pregnant 
women with SLE from 3 to 26%. The frequency of SLE 
relapse during pregnancy in our study population was 
19%. The previous studies have been reported the relapse 
rates ranged from 13 to 68%. Generally, the frequency of 
outcomes evaluated in this study is within the reported 
range from other studies [15–17].
In this study, the increasing SLE duration is signifi-
cantly raised the incidence of some pregnancy com-
plications, including LBW (P = 0.003), pre-eclampsia 
(P = 0.012) and stillbirth (P = 0.036). Impact of disease 
Table 2 Pregnancy outcomes according to  disease 
duration in SLE patients
Outcome Duration of SLE
1–5 year ≥ 6 year P value
PROM 3 (4/3) 3 (5/9) 0.69
LBW 3 (4/3) 11 (21/6) 0.003
Pre-eclampsia 6 (8/6) 13 (25/5) 0.012
Neonatal lupus 1 (1/4) 0 NS
Preterm labor 19 (27/1) 12 (23/5) 0.653
Abortion 30 (42/9) 17 (33/3) 0.289
Still birth 1 (1/4) 5 (8/9) 0.036
Table 3 Association of  predictors with  the  occurrence 
of adverse fetal outcomes in SLE patients by multivariable 
logistic regression analyses
Predictors OR (95% CI) P value
Duration of disease 0.937 (0.217–1.529) 0.229
ESR during pregnancy 0.980 (0.953–1.003) 0.096
CRP during pregnancy 2.896 (0.962–8.674) 0.037
Renal involvement 8.545 (1.396–63.373) 0.017
Anti-ds DNA 0.219 (0.079–0.655) 0.002
APS 5.181 (1.681–13.647) 0.001
Anemia 1.570 (0.676–3.985) 0.320
Age at onset SLE 0.932 (0.865–1.009) 0.018
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duration on pregnancy outcomes has not been evaluated 
in the previous studies.
The results of the present study demonstrate that high 
levels of CRP, APS positivity, anti-dsDNA positivity and 
renal involvement are predictors of adverse pregnancy 
outcomes in SLE patients. These data are in consist-
ent with previous findings [16, 18–20]. The age of SLE 
onset was impressed the pregnancy complications in our 
assessment in contrast with the report of Feld et al. [19].
The impact of SLE renal disease on pregnancy out-
comes is debatable. Several previous studies showed 
that lupus nephritis was significantly linked with severe 
pregnancy outcomes. By contrast, some studies have not 
indicated such relationship [16, 17]. This difference may 
have been created by the number of patients in vari-
ous studies. In addition, study design, population under 
study, treatment or lupus nephritis status may explain the 
different results obtained. Based on our findings, renal 
involvement is an important risk factor for adverse preg-
nancy outcomes, including pre-eclampsia (P = 0.017) and 
still birth (P = 0.042). SLE patients with renal damage 
were 8.5 time (OR = 8.545, CI 1.396–63.373, P = 0.017) 
more likely to have a severe pregnancy outcome. There 
is a significant association between APS and poor 
pregnancy outcomes (P = 0.001), especially abortion 
(P = 0.017), that was similar to several studies [9, 13, 21]. 
This conferred approximately a 5.2-fold increased risk of 
unfavorable outcomes (OR: 5.18, 95% CI 1.681–13.647, 
P = 0.001) when compared to APS-negative patients. Fled 
et  al. also have reported that APS is associated with an 
odds ratio of 5.31 [19].
In conclusion, Frequency of pregnancy complications 
was high in women with pre-existing SLE. The most 
unfavorable pregnancy outcome in women with SLE was 
spontaneous abortion. Duration of SLE prior to preg-
nancy was significantly associated with some outcomes, 
including LBW, pre-eclampsia, and still birth. High CRP, 
renal involvement, anti-dsDNA positivity, APS positivity 
and low age at the onset of the disease increased the risk 
of pregnancy complications.
Limitations
The study limitations were its retrospective nature and 
small sample size. Some pregnant women with SLE (24 
cases) were excluded due to incomplete data in their 
medical records. This study was limited by the amount 
of information obtained from medical records. We could 
not access data on some variables.
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